European Journal of Rheumatology
Invited Review

Targeting IL-17 in psoriatic arthritis

1.

Department of Dermatology, UC Davis School of Medicine, CA, USA

2.

Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, CA, USA

3.

Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, CA, USA; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children Northern California, CA, USA

Eur J Rheumatol 2017; 4: 272-277
DOI: 10.5152/eurjrheum.2017.17037
Read: 493 Downloads: 133 Published: 03 September 2019

Abstract

Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis intimately associated with psoriasis, and can be an impairing disease that leads to reduced quality of life and significant morbidity. Treatment often requires TNF antagonists, yet many patients with PsA are not responsive to the standard anti-TNF therapies. The interleukin-17 (IL-17)/IL-17 receptor (IL-17R) family has recently been implicated in the pathogenesis of PsA and psoriasis. Much enthusiasm has been generated for the development of biologics that target the IL-17 signaling pathway directly or indirectly, many of which have produced striking results in the setting of psoriasis and PsA. Herein, we review the role of IL-17 and the IL-17 receptor (IL-17R) in the pathogenesis of PsA, as well as the clinical evidence for IL-17 and IL-17R targeted therapeutics.

 

 

Cite this article as: Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol 2017; 4: 272-7.

Files
ISSN2147-9720 EISSN 2148-4279